In recent years, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have gained significant attention as effective treatments for type 2 diabetes mellitus (T2DM) and obesity, with emerging potential in renal, pulmonary, and other therapeutic areas. The gene discussed is GCG; the disease is obesity due to melanocortin 4 receptor deficiency.